Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVIDAH
2025-521694-14-00Phase 4Authorised
- Sponsor
- Parc de Salut Mar
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of calcifediol in pulmonary arterial hypertension (PAH), sponsored by Parc de Salut Mar. Primary endpoint: Clinical improvement without clinical worsening. Planned start Sep 2025; status: authorised.
02
Drugs
calcifediol
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2025-521694-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521694-14-00.